Array
(
[1603844648] => Array
(
[wordfence_batchReportBlockedAttempts] => Array
(
[40cd750bba9870f18aada2478b24840a] => Array
(
[schedule] =>
[args] => Array
(
)
)
)
)
[1603844676] => Array
(
[wordfence_processAttackData] => Array
(
[40cd750bba9870f18aada2478b24840a] => Array
(
[schedule] =>
[args] => Array
(
)
)
)
)
[1603844814] => Array
(
[wordfence_hourly_cron] => Array
(
[40cd750bba9870f18aada2478b24840a] => Array
(
[schedule] => hourly
[args] => Array
(
)
[interval] => 3600
)
)
)
[1603845573] => Array
(
[wp_privacy_delete_old_export_files] => Array
(
[40cd750bba9870f18aada2478b24840a] => Array
(
[schedule] => hourly
[args] => Array
(
)
[interval] => 3600
)
)
)
[1603846081] => Array
(
[wpm_update_stats] => Array
(
[40cd750bba9870f18aada2478b24840a] => Array
(
[schedule] => hourly
[args] => Array
(
)
[interval] => 3600
)
)
)
[1603848726] => Array
(
[wp_update_themes] => Array
(
[40cd750bba9870f18aada2478b24840a] => Array
(
[schedule] => twicedaily
[args] => Array
(
)
[interval] => 43200
)
)
[wp_update_plugins] => Array
(
[40cd750bba9870f18aada2478b24840a] => Array
(
[schedule] => twicedaily
[args] => Array
(
)
[interval] => 43200
)
)
)
[1603852153] => Array
(
[wp_version_check] => Array
(
[40cd750bba9870f18aada2478b24840a] => Array
(
[schedule] => twicedaily
[args] => Array
(
)
[interval] => 43200
)
)
)
[1603855073] => Array
(
[wp_session_garbage_collection] => Array
(
[40cd750bba9870f18aada2478b24840a] => Array
(
[schedule] => twicedaily
[args] => Array
(
)
[interval] => 43200
)
)
)
[1603866285] => Array
(
[recovery_mode_clean_expired_keys] => Array
(
[40cd750bba9870f18aada2478b24840a] => Array
(
[schedule] => daily
[args] => Array
(
)
[interval] => 86400
)
)
)
[1603866290] => Array
(
[wp_site_health_scheduled_check] => Array
(
[40cd750bba9870f18aada2478b24840a] => Array
(
[schedule] => weekly
[args] => Array
(
)
[interval] => 604800
)
)
)
[1603868912] => Array
(
[ai1wm_storage_cleanup] => Array
(
[40cd750bba9870f18aada2478b24840a] => Array
(
[schedule] => daily
[args] => Array
(
)
[interval] => 86400
)
)
)
[1603874971] => Array
(
[wp_scheduled_auto_draft_delete] => Array
(
[40cd750bba9870f18aada2478b24840a] => Array
(
[schedule] => daily
[args] => Array
(
)
[interval] => 86400
)
)
)
[1603880111] => Array
(
[delete_expired_transients] => Array
(
[40cd750bba9870f18aada2478b24840a] => Array
(
[schedule] => daily
[args] => Array
(
)
[interval] => 86400
)
)
)
[1603880152] => Array
(
[wpseo-reindex-links] => Array
(
[40cd750bba9870f18aada2478b24840a] => Array
(
[schedule] => daily
[args] => Array
(
)
[interval] => 86400
)
)
)
[1603880814] => Array
(
[wordfence_daily_cron] => Array
(
[40cd750bba9870f18aada2478b24840a] => Array
(
[schedule] => daily
[args] => Array
(
)
[interval] => 86400
)
)
)
[1603892674] => Array
(
[wp_scheduled_delete] => Array
(
[40cd750bba9870f18aada2478b24840a] => Array
(
[schedule] => daily
[args] => Array
(
)
[interval] => 86400
)
)
)
[1603901224] => Array
(
[akismet_scheduled_delete] => Array
(
[40cd750bba9870f18aada2478b24840a] => Array
(
[schedule] => daily
[args] => Array
(
)
[interval] => 86400
)
)
)
[1603904211] => Array
(
[yoast_tracking] => Array
(
[40cd750bba9870f18aada2478b24840a] => Array
(
[schedule] => daily
[args] => Array
(
)
[interval] => 86400
)
)
)
[1603921261] => Array
(
[wpseo_permalink_structure_check] => Array
(
[40cd750bba9870f18aada2478b24840a] => Array
(
[schedule] => daily
[args] => Array
(
)
[interval] => 86400
)
)
[wpseo_home_url_check] => Array
(
[40cd750bba9870f18aada2478b24840a] => Array
(
[schedule] => daily
[args] => Array
(
)
[interval] => 86400
)
)
)
[1603921274] => Array
(
[wpseo-reindex] => Array
(
[40cd750bba9870f18aada2478b24840a] => Array
(
[schedule] => daily
[args] => Array
(
)
[interval] => 86400
)
)
)
[1603979400] => Array
(
[wordfence_start_scheduled_scan] => Array
(
[6c76d3e87c05e58767e709a2328d9fb5] => Array
(
[schedule] =>
[args] => Array
(
[0] => 1603979400
)
)
)
)
[1604238600] => Array
(
[wordfence_start_scheduled_scan] => Array
(
[862e6b127886feed8e1bb7bcc5a0d420] => Array
(
[schedule] =>
[args] => Array
(
[0] => 1604238600
)
)
)
)
[1604329200] => Array
(
[wordfence_email_activity_report] => Array
(
[40cd750bba9870f18aada2478b24840a] => Array
(
[schedule] =>
[args] => Array
(
)
)
)
)
)
Etiquetas: 14 mayo 2007, 14/05/2007, 14/05/2008, 2005/2006, Abatacept, Agencia Europea de Medicamentos, Antibacterianos, Antidiabéticos, Antidiabéticos orales, Antitrombóticos, Autorizaciones de medicamentos, Citostáticos, Colesevelam, Darunavir, Decitabina, Deferasirox, EMEA, Entecavir, Estiripentol, Eszopiclona, Exenatida, Fanolesomab 99 Tc, FDA, Fluoroquinolonas, Food Drug Administration, Gemtuzumab ozogamicina, Grupo, Hormonas hipotalámicas e hipofisarias, Hormonas liberadores de gonadotropinas, Inmunoestimulantes, Inmunosupresores selectivos, Ivermectina, Laboratorio, Laxantes, Lenalidomida, Lubiprostona, Madrid, Medicamento, medicamentos, Micafungina, Natalizumab, Nepafenaco, Nuevos principios activos, PaM digital, Panitumumab, Panorama Actual del Medicamento, Parches de testosterona, Perflutren, Porfímero, Pramlintida, Principio activo, Rimonabant, Rufinamida, salud, Sanidad, Secretina, Sitaxentán, Telbivudina, Temoporfina, Terapia cardiaca, Ziconotida, Zileuton.
.gif)